Research programme: cardiovascular disorder therapeutics - Ascelegen TherapeuticsAlternative Names: GDF11-related therapies - Ascelegen Therapeutics; Growth differentiation factor 11-related therapies - Ascelegen Therapeutics; Growth factor-related therapies - Ascelegen Therapeutics
Latest Information Update: 07 Jul 2014
At a glance
- Originator Ascelegen Therapeutics
- Mechanism of Action Growth differentiation factor 11 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cardiovascular disorders
Most Recent Events
- 19 Jun 2014 Early research in Cardiovascular disorders in USA (unspecified route)